0000000000672888

AUTHOR

Jose G Jimenez

showing 2 related works from this author

A comparison of efficacy and safety of an ezetimibe/simvastatin combination compared with other intensified lipid-lowering treatment strategies in di…

2013

The low-density lipoprotein cholesterol (LDL-C) lowering efficacy of switching to ezetimibe/simvastatin (EZ/S) 10/20 mg versus doubling the run-in statin dose (to simvastatin 40 mg or atorvastatin 20 mg) or switching to rosuvastatin 10 mg in subjects with cardiovascular disease (CVD) and diabetes was assessed. Endpoints included percentage change in LDL-C and percentage of patients achieving LDL-C <70 mg/dL. Significantly greater reductions in LDL-C occurred when switching to EZ/S versus statin doubling in the overall population and in subjects treated with simvastatin 20 mg or atorvastatin 10 mg (all p < 0.001). The LDL-C reduction was numerically greater when switching to EZ/S vers…

MaleSimvastatinEndocrinology Diabetes and MetabolismAtorvastatinEzetimibe Simvastatin Drug CombinationPharmacologySeverity of Illness IndexAtorvastatinLongitudinal StudiesRosuvastatin CalciumAged 80 and overeducation.field_of_studySulfonamidesAnticholesteremic AgentsMiddle AgedRosuvastatin CalciumDrug CombinationsCardiovascular Diseaseslipids (amino acids peptides and proteins)FemaleDrug MonitoringCardiology and Cardiovascular Medicinemedicine.drugmedicine.medical_specialtyStatinmedicine.drug_classPopulationHypercholesterolemiaUrologyDiabetes ComplicationsEzetimibeDouble-Blind MethodInternal MedicinemedicineHumansRosuvastatinPyrrolescardiovascular diseaseseducationAgedbusiness.industrynutritional and metabolic diseasesCholesterol LDLFluorobenzenesPyrimidinesSimvastatinHeptanoic AcidsAzetidinesEzetimibe/simvastatinbusinessDiabetic AngiopathiesDiabetesvascular disease research
researchProduct

Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects

2013

Purpose: This post hoc analysis assessed switching to ezetimibe/simvastatin 10/20 mg vs doubling the baseline statin dose to simvastatin 40 mg or atorvastatin 20 mg or switching to rosuvastatin 10 mg in subgroups of obese (BMI ≥30 kg/m 2 ) and non-obese (BMI <30 kg/m 2 ) diabetic subjects. Methods: This was a randomized, double-blind, 12-week study of adults 18–79 years with cardiovascular disease with low-density lipoprotein cholesterol (LDL-C) ≥70 and ≤160 mg/dl. Percent change in LDL-C and other lipids was estimated. Results: In obese subjects (n = 466), percent changes in LDL-C and most other lipids were greater with ezetimibe/ simvastatin vs doubling the baseline statin dose or switchi…

MaleSimvastatinApolipoprotein BEndocrinology Diabetes and MetabolismAtorvastatinClinical Biochemistrychemistry.chemical_compoundEndocrinologyAtorvastatinRosuvastatin CalciumSulfonamidesNutrition and DieteticsbiologyAnticholesteremic AgentsDiabetesMiddle AgedRosuvastatin CalciumTreatment OutcomeFemalelipids (amino acids peptides and proteins)Cardiology and Cardiovascular Medicinemedicine.drugAdultmedicine.medical_specialtyStatinAdolescentmedicine.drug_classUrologyRosuvastatinYoung AdultEzetimibeDiabetes mellitusInternal medicineInternal MedicinemedicineHumansPyrrolesRosuvastatinObesitycardiovascular diseasesAgedApolipoproteins BBiochemistry medicalCholesterolbusiness.industryResearchBiochemistry (medical)Statinnutritional and metabolic diseasesCholesterol LDLEzetimibemedicine.diseasePeptide FragmentsFluorobenzenesDiabetes Mellitus Type 1PyrimidinesEndocrinologyDiabetes Mellitus Type 2chemistryHeptanoic AcidsSimvastatinbiology.proteinAzetidinesEzetimibe/simvastatinbusinessLipids in Health and Disease
researchProduct